Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract 943: RelA regulates CXCR5/CXCL13 transcription and associated immune response in breast cancer

Sougata Roy Chowdhury, Subir Biswas, Gunjan Mandal and Arindam Bhattacharyya
Sougata Roy Chowdhury
University of Calcutta, Kolkata, India.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Subir Biswas
University of Calcutta, Kolkata, India.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunjan Mandal
University of Calcutta, Kolkata, India.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arindam Bhattacharyya
University of Calcutta, Kolkata, India.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2017-943 Published July 2017
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC

Abstract

It is evident from research outcomes that metastases-associated deaths are predominant in breast cancer. Recent developments on early diagnosis using mammographic screening and the implementation of adjuvant therapies may have reduced breast cancer associated deaths in decent numbers, although new markers for prognosis are of utmost importance for patients with higher risk of developing metastases or recurrence.

Chemokines are the key messenger of cellular immune response and can be targeted to reduce the intratumoral regulatory T cells (Treg) for antitumor immunity. Targeting either specific immunomodulators and/or intervening molecular mechanisms is thought to be a potential therapeutic option. In our previous study, we have found that co-expression of CXCR5 and CXCL13 is significantly associated with epithelial to mesenchymal transition (EMT) of cells and lymph node metastasis (LNM) during breast cancer progression. In this study, we are aiming to investigate how the transcriptional regulation of this receptor-ligand pair directs the process of disease development. Interestingly, it was found that RelA (p65), a subunit of NFkB protein, promoted the transcription of both CXCR5 and CXCL13. The putative RelA binding sites were validated using sequential deletion of respective promoter regions of CXCR5 and CXCL13. We observed that expression of CXCR5 significantly (p<0.05) increased with RelA and Nrf2 overexpression and CXCL13 co-stimulation in MDA-MB-231 cell line. RelA was also found to induce the expression of CXCL13 in T-47D and MDA-MB-231 cell line. Significantly, SNAIL, a key EMT regulatory element, was found to be highly expressed in RelA-transfected MDA-MB-231 cell line with or without CXCR5 and CXCL13 co-stimulation. We also observed CXCR5+ T follicular helper (Tfh) and Treg sub-population within the tumor microenvironment, although numbers varied with stages and molecular subtypes. In chemotaxis assay, CXCR5+ Treg cells were found to be predominant among migratory T-cell subsets against RelA overexpression and/or CXCL13 stimulation. Simultaneously, CCL2, a pro-inflammatory chemokine, induced macrophages to secrete CCL22, which in turn, might attract CXCR5+ Treg and Th2 cells into the tumor microenvironment. Study in 4T1-BALB/c breast cancer mouse model demonstrated significant (p<0.05) increase in CXCR5 and CXCL13 expression levels upon immunostimulation.

The study may help to understand the prognosis value of CXCR5 and CXCL13 considering the impact of this receptor-ligand pair on the regulation of Tfh/Treg ratio, EMT and LNM. We believe that this investigation may lead to a comprehensive prediction of the tumor fate as well as to explore possible markers for breast cancer prognosis and future chemotherapy with more precision.

Citation Format: Sougata Roy Chowdhury, Subir Biswas, Gunjan Mandal, Arindam Bhattacharyya. RelA regulates CXCR5/CXCL13 transcription and associated immune response in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 943. doi:10.1158/1538-7445.AM2017-943

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 77 (13 Supplement)
July 2017
Volume 77, Issue 13 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 943: RelA regulates CXCR5/CXCL13 transcription and associated immune response in breast cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 943: RelA regulates CXCR5/CXCL13 transcription and associated immune response in breast cancer
Sougata Roy Chowdhury, Subir Biswas, Gunjan Mandal and Arindam Bhattacharyya
Cancer Res July 1 2017 (77) (13 Supplement) 943; DOI: 10.1158/1538-7445.AM2017-943

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 943: RelA regulates CXCR5/CXCL13 transcription and associated immune response in breast cancer
Sougata Roy Chowdhury, Subir Biswas, Gunjan Mandal and Arindam Bhattacharyya
Cancer Res July 1 2017 (77) (13 Supplement) 943; DOI: 10.1158/1538-7445.AM2017-943
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Tumor Microenvironment 1

  • Abstract 967: Development of fluorescent-cell based high throughput assay to identify novel therapeutics of bladder cancer cells through upregulation of SPARC expression
  • Abstract 946: Characterize and identify secreted high molecular weight heparanase from PC3M conditioned medium
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement